TREA

98292345 - NEORANKER

Follow

Information

  • Trademark
  • 98292345
  • Serial Number
    98292345
  • Filing Date
    November 30, 2023
    a year ago
  • Transaction Date
    January 23, 2025
    3 days ago
  • Status Date
    January 23, 2025
    3 days ago
  • Location Date
    January 23, 2025
    3 days ago
  • Status Code
    602
  • Current Location
    TMO LAW OFFICE 117
    Employee Name
    LEASER, ANDREW
  • Attorney Name
    Rebecca Liebowitz
    Law Office Assigned Location Code
    M80
  • Owners
Information
Mark Drawing Code
4
Mark Identification
NEORANKER
Case File Statements
  • GS0401: Custom manufacture of therapeutic drugs; namely custom manufacture of cell therapies and cancer therapies
  • GS0091: Bioinformatics software; computer software platforms
  • GS0051: Medical and veterinary preparations for therapeutic purposes; preparations for cancer therapy; antibodies; vaccines; preparations for cell therapy; preparations for modifying human or animal cells for medical or therapeutic purposes; preparations of blood extracted from humans or animals which have been adapted for medical or therapeutic purposes
  • PM0001: NEO RANKER
  • GS0441: Medical services; veterinary services; services in the extraction of human and animal cells from patients; manipulation of human and animal cells for therapeutic purposes; reinsertion of cells into human and animal patients; providing advice and consultancy in the field of medical and veterinary therapies; providing advice and consultancy in the field of cancer therapies
  • GS0421: Scientific and technological services and research and design relating thereto; industrial analysis and research services; medical and veterinary research services including the manipulation of cells within a laboratory or research facility to enable the cells to be used for medical or therapeutic purposes; scientific research in the development of new cancer therapies; scientific research into cancer evolution and clonal architecture; scientific research in human and animal cell therapy; scientific research into vaccines; scientific research into preparations for manipulating and adapting human and animal cells; consultancy relating to all the aforesaid services; Software as a service; providing a bioinformatics platform for manufacturing therapeutics; providing a bioinformatics platform for identifying neoantigens
Case File Event Statements
  • 11/30/2023 - a year ago
    1 - NEW APPLICATION ENTERED Type: NWAP
  • 2/23/2024 - 11 months ago
    2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS
  • 6/28/2024 - 7 months ago
    3 - ASSIGNED TO EXAMINER Type: DOCK
  • 7/5/2024 - 6 months ago
    5 - NON-FINAL ACTION E-MAILED Type: GNRT
  • 7/5/2024 - 6 months ago
    4 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 7/5/2024 - 6 months ago
    6 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN
  • 9/30/2024 - 3 months ago
    8 - APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED Type: XELG
  • 1/23/2025 - 3 days ago
    10 - ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND Type: MAB2
  • 1/23/2025 - 3 days ago
    9 - ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE Type: ABN2
  • 9/30/2024 - 3 months ago
    7 - APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED Type: XELR